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INTRODUCTION AND AIMS: Few studies have evaluated the effect of different
immunosuppressive strategies on long term kidney transplant outcomes. Moreover, as
they were usually based on historical data, it was not possible to account for the pres-
ence of pretransplant donor-specific HLA antibodies (DSA), a currently recognized
important risk marker for impaired graft survival. The aim of this study was to evaluate
the influence of frequently used initial immunosuppressive therapies on graft survival
after first kidney transplantation in patients without pretransplant DSA.
METHODS: We performed a retrospective analysis on the PROCARE cohort, a Dutch
multicenter study including all transplantations performed in the Netherlands between
1995 and 2005 with available pretransplant serum (n¼4770). All sera were assessed for
the presence of DSA by a Luminex single antigen bead assay. 1025 patients were
excluded because of retransplantation (n¼455), the presence of pretransplant DSA
(n¼297) or both (n¼273).
RESULTS: In the remaining cohort three regimes were used in more than 200 patients:
cyclosporine/prednisone (n¼548), cyclosporine/MMF/prednisone (n¼1421) and
tacrolimus/MMF/prednisone (n¼992). Adjusted analysis revealed no significant differ-
ences in 10-year death-censored graft survival between patients on cyclosporine/pre-
dnisone therapy (78%) compared to patients on cyclosporine/MMF/prednisone (83%,
p¼0.20) or tacrolimus/MMF/prednisone (79%, p¼0.45). However, the 1-year rejec-
tion-free survival censored for death and failure unrelated to rejection in patients with-
out induction therapy was significantly higher for tacrolimus/MMF/prednisone (80%)
compared to cyclosporine/MMF/prednisone (67%, p<0.0001) and cyclosporine/pre-
dnisone (63%, p<0.0001). For patients with induction therapy (almost all on triple
therapy), no differences in 1-year rejection-free survival were observed between
patients on cyclosporine/MMF/prednisone or tacrolimus/MMF/prednisone (77% vs.
78%).
CONCLUSIONS: In conclusion, this data suggests that in immunological low risk
patients (first transplantation, no DSA) excellent long term kidney graft survival can be
achieved irrespective of the type of initial immunosuppressive therapy (cyclosporine or
tacrolimus; with or without MMF), despite differences in the incidence of acute rejec-
tion in patients without induction therapy.
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INTRODUCTION AND AIMS: Banff Classification accepts two histomorphological
features as surrogates of HLA Antibody-Antigen interaction on renal endothelium:
C4d staining and microvascular inflammation scores (MVI sum score:ptcþg2) which
are strong predictors of transplant glomerulopathy (TG) and subsequent graft loss.
However, increasing evidence questions the ability of the ptc score to solely mirror all
diagnostic and prognostic aspects of ptc morphology. More recently we observed a
highly significant relationship of diffuse extent of ptc (inflammation of>50% the renal
cortex) with graft loss and significantly higher DSA levels suggesting potential inclusion
of diffuse ptc as an additional surrogate of antibody-antigen interaction.
METHODS: We included 616 patients (Tx 1999-2006) with adequate material for
interpretation of MVI and C4d staining in first indication biopsies. Alternatively we
assessed MVI with an integrated view of ptc morphology including both results of ptc
score and ptc extent: additionally to MVI scores, cases with a ptc score of 1 but diffuse
extent of ptc (ptc 1diffuse, n¼26) and no glomerulitis were added as a surrogate of
antigen-antibody interaction. Outcomes measured were presence of any TG in all indi-
cation biopsies (n¼1619) and death-censored graft loss until 01.01.2017.
RESULTS: Linear C4d in PTCs and MVI scores2 were observed in 11% and 19% of the
specimens. TG (cg score>0) in one or more biopsies was found in 13% of patients. The
incorporation of ptc 1diffuse in addition to the MVI score2 significantly increased the
receiver operating characteristic curve for TG [AUC: 0.613, p¼0.002] compared to the
Banff MVI score2 [AUC: 0.571, p¼0.046]. or C4dþ [AUC: 0.540 (95%CI 0.47-0.61),
p¼0.26]. In multivariate analysis adjusting for multiple confounders, including C4d or
cellular rejection, ptc1diffuse remained independently related to TG (OR 3.88, p¼0.008)
and graft loss (HR 2.64, p¼0.001). Ptc 1diffuse and MVI score2 subjects had similarly
decreased graft survival (44%) compared to patients with ptc 1 focal or without MVI with
best overall survival ( 70% and 68%) after a mean follow-up of 9 years.
CONCLUSIONS: An integrated view of ptc morphology including diffuse ptc in assess-
ing MVI is superior for TG and graft loss risk assessment.
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INTRODUCTION AND AIMS: In 1999, the Eurotransplant Senior Program (ESP) was
implemented within the Eurotransplant kidney allocation scheme, due to an increasing
number of older recipients and donors. The ESP allocates kidneys from deceased-donors
65 years to kidney transplant recipients65 years (ESP-KTRs), and aims to shorten
cold ischemic time by leaving out HLA matching and regional allocation.
METHODS: We analyzed patient and kidney allograft outcomes of 244 ESP-KTRs between
1999 and 2017. All ESP-KTRs were assessed by a questionnaire-based survey with respect
to mental and physical health using the standardized short form-8 questionnaire (SF-8). A
control group of 82 dialysis patients waitlisted within the ESP was used for comparison.
RESULTS: We observed 1-year, 5-year, and 10-year patient survival of 92.5%, 67.6%,
and 38.2%, respectively. Upon multivariate analysis mortality risk factors included pro-
longed initial hospital stay (p¼0.004), male gender (p¼0.017), and time on dialysis
(p¼0.012). 1-year, 5-year, and 10-year death-censored allograft survival was 92.1%,
81.0%, and 70.0%, respectively. Risk factors that were independently associated with
allograft loss included time on dialysis (p<0.001) and acute cellular rejection
(p<0.001). After re-initiation of dialysis treatment after allograft loss median patient
survival was 46 months (range: 0-152 months). No ESP-KTR underwent retransplanta-
tion after allograft loss. We observed 1-year, 5-year, and 10-year uncensored allograft
survival of 85.2%, 55.4%, and 26.7%, respectively. 45.1 % of ESP-KTRs showed delayed
graft function and 3.7% of ESP-KTRs showed primary non-function. Kidney allograft
function at 1-year, 5-years, and 10-years posttransplantation were 44.6mL/min,
40.5mL/min, and 39.1mL/min, respectively. Median physical and mental component
scores (PCS/MCS) of ESP-KTRs were 40.2 (range: 16.9-62.5) and 48.3 (range: 21.1-
62.5), respectively, and significantly higher compared to dialysis patients waitlisted
within the ESP (p<0.05). The only factors, that were independently associated with
inferior PCS and MCS after kidney transplantation, were recipient age (p¼0.013) and
time on dialysis (p¼0.043). 97% of ESP-KTRs who underwent successful kidney trans-
plantation would choose again to do so.
CONCLUSIONS: Kidney transplantation within the ESP shows highly favorable
patient and allograft outcomes independent of recipient and donor age. However, pro-
longed time on dialysis significantly impacts patient and allograft outcomes and
accounts also for inferior quality of life after successful kidney transplantation. This
finding may be attributed to longer time from medical evaluation to transplantation
among those ESP-KTRs and call for more frequent and critical medical re-evaluation.
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Transplantation, Hôpital Nord, CHU de Saint-Etienne, Jean Monnet University, COMUE
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INTRODUCTION AND AIMS: Living kidney donation requires evaluation of renal
function. Recent KDIGO guidelines for living kidney donors suggest using the “best
locally available” technique to evaluate GFR. That could result in using estimated GFR
for some donors and measured GFR for others. However, there is a significant discrep-
ancy between those techniques that could impact the decision to donate.
METHODS: To evaluate the impact of GFR evaluation method on eligibility to dona-
tion we compared measured GFR with exogenous tracer to estimated GFR with 4 equa-
tions (CKD-EPI, MDRD, Full Age Spectrum, and Lund-Malmö). We conducted a
multicentric study on 1743 French living kidney donors with enzymatic creatinine dos-
age and measured GFR.
RESULTS: The CKD-EPI equation has the best overall performance (highest percent-
age of values within 10% or 30% of measured GFR, 48.8% and 94.4% respectively, low-
est rmse, 16.2mL/min/1.73m2). However, decision to donate is frequently based on a
GFR threshold: 256 donors had an eGFRCKD-EPI higher than 90mL/min/1.73m
2 but an
mGFR lower. Similarly 103 donors had an eGFRCKD-EPI higher than 80mL/min/1.73m
2
but an mGFR lower. The CKDEPI equation misclassified 14.7% and 6% of donors
respectively. Alternatively, if decision to donate is based on an age-dependent thresh-
old, we evaluated the ability of the CKDEPI equation to detect donors with an mGFR
below the 2.5th percentile of mGFR for age. Only 2% of the donors with an mGFR below
the 2.5th percentile of mGFR for age also had an eGFRCKD-EPI below the 2.5
th percentile
for age.
CONCLUSIONS: Even with the best overall performance of the CKDEPI equation,
GFR estimation is not adapted to living kidney donors screening. Regardless on the
acceptance criteria (fixed or age-dependent GFR threshold) measured GFR and esti-
mated GFR give significantly different information that could change the decision to
donate.
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INTRODUCTION AND AIMS: A routine method of assessing the risk of renal graft
loss is using of Panel Reactive Antibody (PRA) test, a surrogate indicator of sensitiza-
tion. It is well known, that lower PRA score is associated with higher transplant survival
rate. Our research shows that sometimes a fall in PRA at the point of transplantation
compared to the peak value may lead to an underestimation of the risk.
METHODS: 287 recipients from the waiting list, with anti-HLA antibodies I, II or both
classes (PRA>5%) were included in the study. Patients were screened periodically to
identify PRA and the specificity of antibodies (identifying the intensity of the immuno-
fluorescence of each antibody specificity). Of these recipients, 142 received a kidney
transplant. At the point of the transplantation the patients had no donor specific anti-
bodies. Cross-match (complement-dependent cytotoxicity test) was negative. HLA-
genotyping of recipients was performed using the sequence specific primers method
(A-, B-, DR-loci), antibodies were analysed using the Luminex platform (single anti-
gen-bead based assay). Endpoints - graft loss and number of AMBR episodes. Poisson
regression was used to assess the risk. Median follow up was 6.4 (IQR 3.5; 8.4) years.
RESULTS: In the patients on the waiting list, the PRA, as well as MFI of specific circu-
lating antibodies were not constant in time (fig. 1). Current PRA may decrease over
time to 30-40% of the historical peak (maximum value) PRA. This is accompanied by
a marked reduction in the MFI of some antibodies - sometimes below the lower thresh-
old (but always higher than MFI of self-antigens!), which in this case was 1000. At times
this may lead to an underestimation of the immunological risk.In univariate model, the
increase in current PRA, increase in historical peak PRA and a decrease in DPRA (dif-
ference between peak and current PRA) was associated with an increased risk of ABMR
(p<0.0001 each) and transplant loss (p<0.001 each) (fig. 2). In our opinion, DPRA is a
very ambiguous measure. The inclusion of DPRA in the multivariate model of Poisson
regression shows that an increase in current PRA is associated with increased risk of
humoral rejection (p<0.001), but not with transplant survival (p¼0.17). Whilst histor-
ical peak PRA remains a significant factor for both humoral rejection of the transplant
(p<0.001) and for its survival (p<0.001).
CONCLUSIONS: In the selection of donor-recipient pairs it is necessary to consider
the spectrum of antibodies at the point of the peak (highest) PRA score. A reduction in
this indicator may in some cases be hiding antibodies, which are reactive to donor anti-
gens or to certain epitopes. The using only current PRA value may lead to underestima-
tion of risk.
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